Evrys Bio awarded a supplement to its NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections”
July 22, 2020: In response to emergency research funding for COVID-19, the supplement extends testing of Evrys broad-spectrum antivirals to coronaviruses including SRAS-CoV-2. ABSTRACT
